Research programme: small-molecule cancer therapeutics - CompugenAlternative Names: CGEN-50001
Latest Information Update: 03 Nov 2010
At a glance
- Originator Compugen
- Class Small molecules
- Mechanism of Action Cell death stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 Nov 2010 No development reported for CGEN 50001 - Preclinical for Cancer in Israel (IV)
- 16 Jul 2008 Preclinical trials in Cancer in Israel (IV)